본문 바로가기
주메뉴 바로가기
HLBELL
ABOUT US
Greeting
What We Do
Corporate Philosophy
Main History
Organization
Location
Technology
Hutrigel® (Human Extracellular Matrix)
BleeFix® (Hemostat)
LifeLiver® (Bioartificial Liver Support System)
Hair Cell Therapeutic
Intellectual Property Rights
Pipeline
Development Stage
Product
Hutrigel®-RU
Primary Human Hepatocytes
Primary Animal Hepatocytes
Medical Plastic
PR
Notice
News
Sitemap
Contact
ENG
KOR
ENG
ABOUT US
Greeting
What We Do
Corporate Philosophy
Main History
Organization
Location
Technology
Hutrigel® (Human Extracellular Matrix)
BleeFix® (Hemostat)
LifeLiver® (Bioartificial Liver Support System)
Hair Cell Therapeutic
Intellectual Property Rights
Pipeline
Development Stage
Product
Hutrigel®-RU
Primary Human Hepatocytes
Primary Animal Hepatocytes
Medical Plastic
PR
Notice
News
SITEMAP
ABOUT US
Greeting
What We Do
Corporate Philosophy
Main History
Organization
Location
Technology
Hutrigel® (Human Extracellular Matrix)
BleeFix® (Hemostat)
LifeLiver® (Bioartificial Liver Support System)
Hair Cell Therapeutic
Intellectual Property Rights
Pipeline
Development Stage
Product
Hutrigel®-RU
Primary Human Hepatocytes
Primary Animal Hepatocytes
Medical Plastic
PR
Notice
News
PR
Biotech Company Specialized in Regenerative Medicine
News
Notice
News
News
HLB셀 ‘수술용 지혈제’, 식약처에서 임상 변경 계획 승인
Date 2022.01.26
Hit 890
기사원문 :
https://biz.chosun.com/it-science/bio-science/2022/01/19/XORFAWFKUNBQZKGWVMOR6Z5PYM/
PREV
HLB셀, 범부처전주기의료기기 연구개발사업 대상자 선정
NEXT
HLB그룹, 신약·백신유통사 900억원에 인수
LIST